Physician profile
Ronald Smith
NPI 1346235850
$1,496.32
in general payments reported to CMS, 2019-2025
26 companies · $23.32 in 2025
The $23.32 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $79.04 · 2021: $364 · 2022: $321 · 2023: $396 · 2024: $22.36 · 2025: $23.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.79 | 2019-2023 | Liletta |
| Astellas Pharma US INC | $118.11 | 2023 | Veozah |
| Organon LLC | $69.53 | 2021-2025 | Nexplanon, Jada System |
| Aspira Women'S Health INC | $54.78 | 2021 | |
| Hologic Sales and Service, LLC | $49.92 | 2022-2023 | Acessa Provu System, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $46.66 | 2023 | |
| Exeltis, USA INC. | $42.53 | 2023 | Slynd |
| Pfizer INC. | $38.97 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $36.95 | 2023-2025 | Euflexxa |
| Sumitomo Pharma America, INC. | $34.98 | 2023 | Myfembree |
| Mayne Pharma Commercial LLC | $27.48 | 2022-2023 | |
| Axonics, INC. | $24.25 | 2021 | |
| Allergan, INC. | $23.99 | 2019-2020 | |
| Coopersurgical, INC. | $22.36 | 2024 | Summit Doppler |
| Duchesnay USA Incorporated | $21.32 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $18.62 | 2019 | |
| Davol INC. | $17.95 | 2022 | |
| Minerva Surgical, INC | $16.13 | 2023 | |
| Amag Pharmaceuticals, INC. | $15.31 | 2019 | |
| Avion Pharmaceuticals | $15.00 | 2022 | |
| Therapeuticsmd, INC. | $14.88 | 2022 | |
| Evofem Biosciences, INC. | $14.28 | 2021 | |
| Avanos Medical | $14.20 | 2019 | |
| Daiichi Sankyo INC. | $13.94 | 2023 | Injectafer |
| Virtus Pharmaceuticals LLC | $12.97 | 2021 | |
| Merck Sharp & Dohme LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.